Skip to main content
Clinical Trials/JPRN-UMIN000006710
JPRN-UMIN000006710
Completed
未知

Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancer - Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancer

Shiga University of Medical Science0 sites30 target enrollmentNovember 14, 2011
ConditionsBreast cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Shiga University of Medical Science
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 14, 2011
End Date
October 31, 2013
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Inflammatory breast cancer (2\)Serious underlying disease (3\)Pregnant or lactating patients (4\)Cumulative administration of previous treatment is \> 360 mg/m2 of doxorubicin or \> 720 mg/m2 of epirubicin (5\)Ineligible based on physicians' decision

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study with hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled studyModerate-to-severe COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-003614-13-ITImmuneMed Inc.105
Completed
Phase 2
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patients
IRCT20151227025726N20Shahid Beheshti University of Medical Sciences80
Active, not recruiting
Phase 1
Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia
EUCTR2019-003821-70-PLAmerican Regent, Inc.10
Recruiting
Phase 2
Investigating the effect of the bone marrow-drived mesenchymal stem cells in MS patients under fingolimod therapy.
IRCT20191004044975N1Vice-presidency for science and technology120
Active, not recruiting
Not Applicable
intravenous immunoglobulin for the treatment of infections in patients with post solid organ transplantation hypogammaglobulinemiainfections in patients with post solid organ transplantation IgG hypogammaglobulinemiaMedDRA version: 15.0Level: LLTClassification code 10054427Term: HypogammaglobulinemiaSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2012-001327-12-ESFundacion para la Investigación Biomédica del Hospital Gregorio Marañón